Inhibition of Notch1 intracellular domain fragment transfected in human HeLa cells co-transfected with CBF1-PGL3 luciferase reporter vector by transactivation assay
Transactivation Assay: The Notch-CBF1 (C-promoter binding factor I) cell based transactivation assay is based on the ability of the released Notch intracellular domain fragments (NICDs) to function as transcription factors in conjunction with CBF1 and other nuclear factors. Luciferase assays were used to measure the antagonism of Notch-CBF1 transcriptional activity. HeLa cervical cancer cells are transiently co-transfected with pCDNA3.1/Hygro plasmids containing truncated Notch 1, Notch 2, Notch 3, or Notch 4 receptors and a PGL3 luciferase reporter vector containing 4 copies of CBF1 binding site. The cells were then tested for Notch-CBF1 activity in the absence or presence of test compounds. HeLa cells, maintained in DMEM (high glucose with HEPES), 1× glutamine/penicillin/streptomycin and 10% Fetal Bovine serum, were transiently transfected in a T175 Flask (4.5×106 cells/flask) using the Monster Transfection Kit (Minis #MIR2906) according to manufacturers specifications.
Transactivation Assay: The Notch-CBF1 (C-promoter binding factor I) cell based transactivation assay is based on the ability of the released Notch intracellular domain fragments (NICDs) to function as transcription factors in conjunction with CBF1 and other nuclear factors. Luciferase assays were used to measure the antagonism of Notch-CBF1 transcriptional activity. HeLa cervical cancer cells are transiently co-transfected with pCDNA3.1/Hygro plasmids containing truncated Notch 1, Notch 2, Notch 3, or Notch 4 receptors and a PGL3 luciferase reporter vector containing 4 copies of CBF1 binding site. The cells were then tested for Notch-CBF1 activity in the absence or presence of test compounds. HeLa cells, maintained in DMEM (high glucose with HEPES), 1× glutamine/penicillin/streptomycin and 10% Fetal Bovine serum, were transiently transfected in a T175 Flask (4.5×106 cells/flask) using the Monster Transfection Kit (Minis #MIR2906) according to manufacturers specifications.
Inhibition of recombinant mouse N-terminal FLAG-tagged Notch1 (1704 to 2531 residues) expressed in human LS174T cells assessed as reduction in doxycycline-induced NICD expression after 12 hrs by Bright-Glo luciferase reporter gene assay
Inhibition of doxycycline-induced recombinant mouse N-terminal FLAG-tagged Notch1 (1704 to 2531 residues) activation expressed in human LS174T cells assessed as reduction in Hes1 level at 0.1 to 1 uM after 12 hrs by Western blot analysis
Inhibition of doxycycline-induced recombinant mouse N-terminal FLAG-tagged Notch1 (1704 to 2531 residues) activation expressed in human LS174T cells assessed as reduction in Hes5 level at 0.1 to 1 uM after 12 hrs by Western blot analysis
Inhibition of Notch1 in human HPBALL cells assessed as reduction in NICD expression at 0.5 uM after 12 hrs in presence of proteasome inhibitor MG132 by Western blot analysis
Inhibition of NOTCH1 signalling in human KOPTK1 cells harboring activating Notch1 gene mutations assessed as reduction in N1Val protein expression at 2.5 uM incubated for 36 hrs by Western blot analysis
Inhibition of NOTCH1 signalling in human KOPTK1 cells harboring activating Notch1 gene mutations assessed as reduction in DELTEX1 mRNA expression at 2.5 uM incubated for 36 hrs by RT-PCR analysis